Bank Of New York Mellon Corp Cor Medix Inc. Transaction History

Bank Of New York Mellon Corp

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$3.22 - $4.61 $77,331 - $110,713	24,016 New	24,016 $99.4 Million
Q4 2022 Feb 14, 2023	BUY	$2.81 - $4.45 $67,484 - $106,871	24,016 New	24,016 $101,000
Q2 2022 Aug 15, 2022	SELL	$2.73 - $5.61 $277,927 - $571,126	-101,805 Reduced 80.87%	24,078 $97,000
Q1 2022 May 11, 2022	BUY	$3.83 - $6.24 $4,795 - $7,812	1,252 Added 1.0%	125,883 $690,000
Q4 2021 Feb 11, 2022	BUY	$4.47 - $5.56 $7,661 - $9,529	1,714 Added 1.39%	124,631 $567,000
Q3 2021 Nov 12, 2021	BUY	$4.46 - $7.11 $36,598 - $58,344	8,206 Added 7.15%	122,917 $571,000
Q2 2021 Aug 11, 2021	BUY	$6.05 - $10.09 $120,062 - $200,236	19,845 Added 20.92%	114,711 $786,000
Q1 2021 May 13, 2021	SELL	$6.84 - $17.58 $29,220 - $75,101	-4,272 Reduced 4.31%	94,866 $947,000
Q4 2020 Feb 09, 2021	BUY	$5.0 - $9.15 $39,355 - $72,019	7,871 Added 8.62%	99,138 $736,000
Q3 2020 Nov 12, 2020	SELL	$3.96 - $6.15 $3,666 - $5,694	-926 Reduced 1.0%	91,267 $550,000
Q2 2020 Aug 12, 2020	BUY	$3.08 - $6.56 $7,102 - $15,127	2,306 Added 2.57%	92,193 $580,000
Q1 2020 May 06, 2020	BUY	$2.35 - $7.08 $12,798 - $38,557	5,446 Added 6.45%	89,887 $322,000
Q4 2019 Feb 14, 2020	BUY	$4.96 - $7.75 $31,505 - $49,228	6,352 Added 8.13%	84,441 $614,000
Q3 2019 Nov 07, 2019	SELL	$6.38 - $9.69 $905 - $1,375	-142 Reduced 0.18%	78,089 $498,000
Q2 2019 Aug 12, 2019	BUY	$5.93 - $10.57 $297,401 - $530,106	50,152 Added 178.61%	78,231 $701,000
Q1 2019 May 14, 2019	BUY	$6.95 - $13.25 $195,149 - $372,046	28,079 New	28,079 $265,000

109

17.4M

134K

441K

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $502M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.